Evidence map›Paper›PMID 30504225›Full record

ArticleThe Journal of biological chemistry2019

Effects of nuclear factor I phosphorylation on calpastatin (

The Minh Vo, Rebecca Burchett, Miranda Brun, Elizabeth A Monckton, Ho-Yin Poon, Roseline Godbout

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

The Minh VoDepartment of Oncology, University of Alberta, Cross Cancer Institute, Edmonton, Alberta T6G 1Z2, Canada.
Rebecca BurchettDepartment of Oncology, University of Alberta, Cross Cancer Institute, Edmonton, Alberta T6G 1Z2, Canada.
Miranda BrunDepartment of Oncology, University of Alberta, Cross Cancer Institute, Edmonton, Alberta T6G 1Z2, Canada.
Elizabeth A MoncktonDepartment of Oncology, University of Alberta, Cross Cancer Institute, Edmonton, Alberta T6G 1Z2, Canada.
Ho-Yin PoonDepartment of Oncology, University of Alberta, Cross Cancer Institute, Edmonton, Alberta T6G 1Z2, Canada.
Roseline GodboutDepartment of Oncology, University of Alberta, Cross Cancer Institute, Edmonton, Alberta T6G 1Z2, Canada. Electronic address: rgodbout@ualberta.ca.
University of Alberta · CA

Funding

CIHR 130314
6 · The paper itself

Abstract

Malignant glioma (MG) is the most lethal primary brain tumor. In addition to having inherent resistance to radiation treatment and chemotherapy, MG cells are highly infiltrative, rendering focal therapies ineffective. Genes involved in MG cell migration and glial cell differentiation are up-regulated by hypophosphorylated nuclear factor I (NFI), which is dephosphorylated by the phosphatase calcineurin in MG cells. Calcineurin is cleaved and thereby activated by calpain proteases, which are, in turn, inhibited by calpastatin (CAST). Here, we show that the

Indexed as

Gene Expression Regulation, NeoplasticMutationBinding SitesCalcium-Binding ProteinsCell MovementGliomaHumansNeurofibromin 1PhosphorylationPromoter Regions, GeneticSubcellular FractionsTumor Cells, CulturedCalcium-Binding ProteinscalpastatinNeurofibromin 1NF1 protein, humanbrain tumorcalcineurincalpaincalpastatincancer biologycell signalingchromatin immunoprecipitation (ChIP)cysteine proteasegel shiftsgene regulationglioblastomaimmunofluorescencemalignant gliomanuclear factor Iprotein phosphorylationtranscription factor

Identifiers

PMID30504225
PMCPMC6349116
OpenAlexW2903348670

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.